Cartesian Therapeutics (RNAC) Gains from Investment Securities (2015 - 2026)
Cartesian Therapeutics (RNAC) reported Gains from Investment Securities of -$94000.0 for Q1 2026, up 94.83% year-over-year from -$48247.3 in Q1 2025, and up 97.46% quarter-over-quarter from -$3.7 million in Q4 2025.
Cartesian Therapeutics (RNAC) Gains from Investment Securities (2015 - 2026) Analysis & Trends
Cartesian Therapeutics (RNAC) has 12 years of Gains from Investment Securities data on file, last reported at -$94000.0 in Q1 2026.
- Gains from Investment Securities for Q1 2026 came in at -$94000.0, up 94.83% year-over-year; the trailing twelve-month figure through Mar 2026 was -$5.0 million (down 539.05% YoY), and the FY2025 annual result was -$3.7 million, changed N/A from the prior year.
- Gains from Investment Securities advanced to -$94000.0 in Q1 2026 per RNAC's latest filing, from -$3.7 million in the prior quarter.
- Over five years, Gains from Investment Securities peaked at $6.5 million in Q3 2022 and troughed at -$21.0 million in Q4 2022.
- A 5-year average of -$2.5 million and a median of -$654000.0 in 2025 frame the typical range for Gains from Investment Securities.
- On a YoY basis, Gains from Investment Securities climbed as much as 1204.56% in 2022 and fell as far as 999.06% in 2022.
- A 5-year view of Gains from Investment Securities shows it stood at -$21.0 million in 2022, then jumped by 97.73% to -$477000.0 in 2023, then jumped by 687.63% to $2.8 million in 2024, then slumped by 231.82% to -$3.7 million in 2025, then jumped by 97.46% to -$94000.0 in 2026.
- Business Quant data shows RNAC's Gains from Investment Securities at -$94000.0 in Q1 2026, -$3.7 million in Q4 2025, and -$516000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Cartesian Therapeutics | 261.84 Mn | 261.84 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -94,000.00 |
| Mar 31, 2026 | -94,000.00 |
| Dec 31, 2025 | -3.70 Mn |
| Dec 31, 2025 | -3.70 Mn |
| Sep 30, 2025 | -516,000.00 |
| Sep 30, 2025 | -516,000.00 |
| Jun 30, 2025 | -654,000.00 |
| Jun 30, 2025 | -654,000.00 |
| Mar 31, 2025 | -1.82 Mn |
| Mar 31, 2025 | -1.82 Mn |
| Dec 31, 2024 | 2.80 Mn |
| Dec 31, 2024 | 2.80 Mn |
| Sep 30, 2024 | -5.67 Mn |
| Sep 30, 2024 | -5.67 Mn |
| Jun 30, 2024 | 3.91 Mn |
| Jun 30, 2024 | 3.91 Mn |
| Mar 31, 2024 | -1.04 Mn |
| Mar 31, 2024 | -1.04 Mn |
| Dec 31, 2023 | -477,000.00 |
| Dec 31, 2023 | -477,000.00 |